ライフサイエンスコーパス: functional outcome

1 of fragmented IP3R1 can result in a distinct functional outcome.

2 sduced into structural changes and hence the functional outcome.

3 he psychosis spectrum and is associated with functional outcome.

4 of spontaneous circulation (ROSC) and a good functional outcome.

5 he prediction of both treatment response and functional outcome.

6 farction as a biosignal for left ventricular functional outcome.

7 C with the development of psychosis and with functional outcome.

8 Complete recanalisation may influence functional outcome.

9 aumatic amnesia is an important predictor of functional outcome.

10 pital discharge, and survival with favorable functional outcome.

11 , calcium dynamics were used as a measure of functional outcome.

12 ectal grade, local recurrence, survival, and functional outcome.

13 injuries has a long-term negative impact on functional outcome.

14 e impairments in social cognition and global functional outcome.

15 e cerebral disability) was considered a good functional outcome.

16 visual acuities (BCVAs) were compared as the functional outcome.

17 reperfusion rates and may improve long-term functional outcome.

18 cklist Individual Strength questionnaire and functional outcome.

19 reperfusion, early neurologic recovery, and functional outcome.

20 haracteristics were associated with improved functional outcome.

21 fied Rankin Scale score, 0-3) vs unfavorable functional outcome.

22 n stabilizing the interaction or mediating a functional outcome.

23 roke patients and a strong predictor of poor functional outcome.

24 es of EAP, cognition, clinical symptoms, and functional outcome.

25 DHC on long-term ischemic stroke injury and functional outcome.

26 alteplase versus saline irrigation improved functional outcome.

27 among EAP, cognition, negative symptoms, and functional outcome.

28 ulation, the ischaemic penumbra and clinical functional outcome.

29 ss, and/or cerebral edema may predict better functional outcome.

30 eta = -0.75, P < .001) had direct effects on functional outcome.

31 ne involvement, with satisfying cosmetic and functional outcomes.

32 an incremental clinical benefit in terms of functional outcomes.

33 determine which care processes can maximize functional outcomes.

34 act of prior chronic disease status on these functional outcomes.

35 ng-term physical, cognitive, behavioral, and functional outcomes.

36 therapies to attenuate adverse metabolic and functional outcomes.

37 d practice-related factors on healthcare and functional outcomes.

38 utions at either site should produce similar functional outcomes.

39 elayed cerebral ischaemia (DCI), and 3-month functional outcomes.

40 nts in shorter- and longer-term clinical and functional outcomes.

41 show social impairments that are related to functional outcomes.

42 the nature of antigen presentation dictates functional outcomes.

43 on-Th17 cell features that lead to different functional outcomes.

44 postoperative and oncological results and on functional outcomes.

45 SAH and predicts future ischaemia and worse functional outcomes.

46 associated with increased mortality and poor functional outcomes.

47 orrelate with histological axonal injury and functional outcomes.

48 isk factor for deleterious mental health and functional outcomes.

49 high cure rates, and acceptable cosmetic and functional outcomes.

50 elation to meta-cognition in determining its functional outcomes.

51 ondly whether they can independently predict functional outcomes.

52 causal link between T cell-DC behaviour and functional outcomes.

53 with a 2.3-fold reduced lesion and improved functional outcomes.

54 velop post-injury epilepsy tend to have poor functional outcomes.

55 cant deficiencies of T and NK cells and poor functional outcomes.

56 evice and assessed its early performance and functional outcomes.

57 ia impacts clinical or left ventricular (LV) functional outcomes.

58 dict beneficial clinical, neurocognitive and functional outcomes.

59 patients is safe, feasible, and may improve functional outcomes.

60 sening retinopathy with objectively measured functional outcomes.

61 and deep retinal plexuses, correlating with functional outcomes.

62 cteristics associated with better (or worse) functional outcomes.

63 in somatosensory processing, leading to poor functional outcomes.

64 caffeine therapy is associated with improved functional outcomes 11 years later.

65 ogical, and neurorehabilitation details with functional outcomes 18 months after heterologous bilater

66 g 1176 individuals for analysis of long-term functional outcome, 853 for analysis of hematoma enlarge

67 e predictive value of plasma GPBB for 90-day functional outcome, 90-day survival and acute lesion vol

68 mmon odds ratio for a shift towards a better functional outcome according to the mRS for intra-arteri

69 Survival and functional outcomes achieved with expanded criteria dono

70 tom relief, pain intensity, quality of life, functional outcomes, adverse events, misuse or diversion

71 ut microbiota affected neuroinflammatory and functional outcome after brain injury.

72 to the results from trials, does not improve functional outcome after intracerebral haemorrhage.

73 al specimen did not compromise oncologic and functional outcome after laparoscopic surgery for low re

74 for sensitive and graduated prognosis of the functional outcome after MI without gadolinium-based con

75 Functional outcome after rehabilitation was assessed usi

76 ective and leads to better physiological and functional outcome after stroke.

77 ould have more CV, DCI, mortality, and worse functional outcomes after aSAH.

78 Evidence suggests that functional outcomes after TBI can show improvement or de

79 onclusion Fast reperfusion leads to improved functional outcome among patients with acute stroke trea

80 nterventions targeting these factors improve functional outcomes among older ICU survivors.

81 fect of bystander interventions on long-term functional outcomes among survivors of out-of-hospital c

82 re may partially account for the variance in functional outcomes among veterans who sustained combat-

83 s is essential given the strong link between functional outcome and cognitive impairment in schizophr

84 acute ischemic stroke (AIS), indicating poor functional outcome and increased mortality.

85 tic significance of plasma copeptin level on functional outcome and mortality in patients with acute

86 provide better prognostic information about functional outcome and mortality in patients with acute

87 hether autonomic markers are associated with functional outcome and mortality independently of intrac

88 Long-term functional outcome and risk of fatal or disabling stroke

89 f life, and delayed postoperative morbidity (functional outcome and sensory disorders) were assessed

90 To compare functional outcomes and adverse effects associated with

91 ersistent moderate to severe depression, but functional outcomes and economic benefits are equivocal.

92 l care with tPA was associated with improved functional outcomes and higher rates of angiographic rev

93 h focal and global CV and also predicts poor functional outcomes and mortality after aSAH.

94 t conformations of a GPCR linked to distinct functional outcomes and offers the prospect of designing

95 Overall functional outcomes and QOL scores were acceptable.

96 ecline or increasing GABA levels may improve functional outcomes and quality of life as patients with

97 We evaluate long-term functional outcomes and safety of posterior chamber IOL

98 relationship between vasospasm and long-term functional outcomes and should also evaluate potential p

99 To compare neurocognitive and endocrine functional outcomes and survival at 5 years in young pat

100 Interestingly, long-term functional outcomes and survival rates were similar betw

101 s associated with higher rates of favourable functional outcome, and lower rates of symptomatic intra

102 subgroups, dose-response, length of therapy, functional outcome, and quality of life after beta-block

103 mining endovascular therapy yielded variable functional outcomes, and the effect of endovascular inte

104 H volume, haematoma expansion, mortality and functional outcome appear to be similar for NOAC-ICH ver

105 Randomized controlled trials with functional outcomes are needed to establish the most eff

106 rygium surgery was associated with a similar functional outcome as that of Vicryl sutures in terms of

107 was associated with a durable improvement in functional outcomes as assessed by Rotarod and Morris Wa

108 ajor adverse events, and quality of life and functional outcomes as assessed by the EuroQOL-5D qualit

109 Fatigue was associated with a poor functional outcome, as assessed by the mRS (OR 4.0 (95%

110 ter stroke provided long-term improvement in functional outcome, as DHC-treated mice exhibited improv

111 The primary outcome was functional outcome, as measured by the modified Rankin S

112 e with mortality as the primary endpoint and functional outcome, as well as hippocampal cellular and

113 Following implantations, anatomic and functional outcomes, as well as ocular complications, we

114 The primary outcome was functional outcome assessed by ordinal analysis of the m

115 significant benefit in survival with a good functional outcome at 1 year.

116 ificant benefit in survival with a favorable functional outcome at 1 year.

117 y after SAH and a predictor of death or poor functional outcome at 12 months.

118 on size 2 days after ischemia but did worsen functional outcome at 14 days and increase lesion size a

119 neficial effect of endovascular treatment on functional outcome at 2 years in patients with acute isc

120 collaterals increased the rate of favourable functional outcome at 3 months (RR=1.98, 95% CI 1.64 to

121 Endovascular thrombectomy improved functional outcome at 3 months both in patients who had

122 cardial infarction correlated inversely with functional outcome at 6 months.

123 safety, such as bleeding or infections, and functional outcome at 90 and 180 days.

124 (OR = 0.869;CI, 0.445-1.695; p = 0.680) and functional outcome at 90 days (OR = 0.478; CI, 0.190-1.2

125 The primary outcome was a good functional outcome at 90 days, defined as a Glasgow Outc

126 days (80% vs. 37%, P=0.002) and improved the functional outcome at 90 days, with more patients achiev

127 and the modified Rankin Scale (mRS) assessed functional outcome at 90 days.

128 intracerebral haemorrhage in the context of functional outcome at 90-180 days.

129 % CI 0.42 to 1.05, p=0.077) and unfavourable functional outcome at discharge (OR: 0.77; 95% CI 0.41 t

130 Survival to hospital discharge and functional outcome at hospital discharge.

131 ng compared with surgery resulted in similar functional outcomes at 6 months.

132 etriever within 6 hours after onset improved functional outcomes at 90 days.

133 There was a trend toward improved functional outcomes at follow-up with CarePath implement

134 with alteplase did not substantially improve functional outcomes at the mRS 3 cutoff compared with ir

135 1 to 8, with lower scores indicating a worse functional outcome) at 6 months.

136 aling cascade that culminates in many of the functional outcomes attributed to 20-HETE in vitro and i

137 They are also associated with worse functional outcome, but this finding appears to be relat

138 hese difficulties are strongly predictive of functional outcomes, but there is a paucity of effective

139 Secondary outcomes were functional outcome by modified Rankin Scale (mRS) after

140 tically augmenting efferocytosis may improve functional outcomes by both reducing tissue injury and p

141 engineering of this hotspot induces opposing functional outcomes by Stg and CNIH3.

142 t visual rehabilitation with relatively good functional outcomes can be achieved by performing repeat

143 for symptomatic end-stage disease, although functional outcomes can be poor and the lifespan of pros

144 20 +/- 7% (mean +/- SD; p < 0.05) and better functional outcome compared with controls.

145 fter usual care was associated with improved functional outcomes compared with usual care alone, and

146 ut-of-hospital cardiac arrests in Denmark to functional outcome data and reported the 1-year risks of

147 e at reduced risk for radiographic nonunion; functional outcome data are limited and requires increas

148 imaging), electrophysiological, and 3-month functional outcome data were collected.

149 CI]: 1.22 to 1.72; p < 0.0001) and excellent functional outcome defined as mRS 0 to 1 (RR: 1.67; 95%

150 ed with a higher incidence of achieving good functional outcome, defined as a modified Rankin scale (

151 The primary efficacy outcome was good functional outcome, defined as a modified Rankin Scale s

152 In addition, functional outcome, defined as changes in New York Heart

153 able, regression models to predict long-term functional outcome (dichotomizations of the Glasgow Outc

154 r brain developmental trajectories predicted functional outcomes during late adolescence.

155 s multicenter study aims to assess long-term functional outcome, early and late (mesh-related) compli

156 lume in infancy is associated with long-term functional outcomes, emphasizing the persisting influenc

157 Overall, EAP had a fully mediated effect on functional outcome, engaging general rather than modalit

158 oke survivors and was associated with a poor functional outcome, even after almost a decade of follow

159 Recorded were the 3-month functional outcome, factors associated with an unfavorab

160 independent predictor of mortality and poor functional outcomes following ICH.

161 have been demonstrated to improve long-term functional outcomes following intracerebral hemorrhage (

162 To help understand individual differences in functional outcomes following neuro-oncological treatmen

163 may provide more effective ways to maximise functional outcomes following severe peripheral nerve tr

164 Here, we assessed long-term functional outcomes following subretinal delivery of the

165 treatments demonstrated to improve long term functional outcomes following traumatic brain injury(TBI

166 eizures were associated with worse long-term functional outcome (hazard ratio 1.83, P = 0.005), but t

167 Secondary outcome measures were functional outcome, health-related quality of life, and

168 ing and plating provide equivalent long-term functional outcomes; however, plating may lead to a high

169 5% CI = 0.17-0.45, p < 0.0001) and favorable functional outcome (HR = 4.08, 95% CI = 2.48-6.72, p < 0

170 l [CI] = 0.14-0.44, p < 0.0001) and improved functional outcome (HR = 4.22, 95% CI = 2.57-6.94, p < 0

171 recanalisation had a greater chance of good functional outcome (HR=5.17; 95% CI=2.8 to 9.53, p<0.001

172 Indeed, inhibition of Gli1 improves the functional outcome in a relapsing/remitting model of exp

173 ndividual, aesthetically appealing, and good functional outcome in addition to high patient satisfact

174 inant tissue plasminogen activator (rtPA) on functional outcome in ischaemic stroke is clear, but the

175 We assessed functional outcome in ischaemic stroke patients with lar

176 oke fatigue negatively influences short-term functional outcome in older stroke survivors.

177 ion duration on the probability of favorable functional outcome in out-of-hospital cardiac arrest usi

178 cranial arterial occlusion leads to improved functional outcome in patients treated within 6 hours af

179 of body mass index (BMI) with mortality and functional outcome in patients with acute ischemic strok

180 acid is superior to placebo in improving the functional outcome in patients with acute stroke and hyp

181 cognitive reserve on long-term cognitive and functional outcome in patients with different degrees of

182 of the factors most strongly associated with functional outcome in schizophrenia, current treatment s

183 s only proven beneficial to histological and functional outcome in studies in which the rate of subcl

184 re expected to elucidate the distribution of functional outcome in survivors.

185 ts fail to form lytic synapses, however, the functional outcome in vivo remains unknown.

186 likewise improves muscle histopathology and functional outcomes in affected mice.

187 mechanisms give rise to radically different functional outcomes in each family of HORMA domain prote

188 Long-term functional outcomes in everyday settings, as assessed th

189 led to nearly equivalent graft survival and functional outcomes in HS pediatric patients as nonsensi

190 ectively activate these neurons and analyzed functional outcomes in mice.

191 cated in valuation, emotional appraisal, and functional outcomes in pain and other types of affective

192 ecovery therapy might be useful in improving functional outcomes in people with first-episode psychos

193 senger with the ability to generate multiple functional outcomes in response to different extracellul

194 , contributing to significantly better motor functional outcomes in subacute stroke patients with sev

195 would be superior to alteplase in improving functional outcomes in the group of patients with target

196 ial Il6 gene expression in vivo and improved functional outcomes in the murine model.

197 This study sought to assess clinical and functional outcomes in women with PPCM complicated by pr

198 ckholm and Helsinki CT scores for predicting functional outcome, in comparison with the Rotterdam CT

199 luemean was associated with left ventricular functional outcome independent of infarct size (Delta ej

200 Predictions of long-term survival and functional outcomes influence decision making for critic

201 However, proof of a beneficial effect on functional outcome is lacking.

202 clot removal is safe and can achieve a good functional outcome is not known.

203 The functional outcome is predicted for over a hundred thyro

204 The benefit of hypothermia on functional outcome is unclear.

205 absence of C5aR ultimately leading to poorer functional outcomes, larger lesion volumes, reduced myel

206 hich were later associated with differential functional outcome (left ventricular ejection fraction d

207 The effects of arterial oxygenation on functional outcome, long-term mortality, and discharge v

208 Two trials found no difference in functional outcome (MD = -0.88; 95% CI -6.63 to 4.87; p

209 e, we demonstrate that aducanumab reverses a functional outcome measure reflective of neural network

210 Functional outcomes measured by the absolute value and t

211 trials, which to date have relied solely on functional outcome measures for patient enrollment, stra

212 disease (STGD) and correlate these data with functional outcome measures.

213 excellent results, as measured by objective functional outcome measures.

214 Treatment-associated benefits on functional outcomes might warrant further investigation.

215 ssociated with: (1) mortality, (2) favorable functional outcome (modified Rankin Scale = 0-3), and (3

216 ome measures were mortality and unfavourable functional outcome (modified Rankin Score: 4-6) at disch

217 92%]; number needed to treat, 43) and better functional outcomes (modified Rankin Scale score, 0-1) a

218 Poor functional outcome (mRS = 4-6) for score levels 1 throug

219 ell interactions are transduced into diverse functional outcomes necessitates correlated measurements

220 lly matched hESCs and hiPSCs neither predict functional outcome nor distinguish an independently deri

221 We examine the functional outcome of 39 variants associated with System

222 effective in fine grained prediction of the functional outcome of a mutation, and can be used to hel

223 es and computationally defines four types of functional outcome of a variant: gain, loss, switch, and

224 s provides a unique and direct vision of the functional outcome of an organism's activities that are

225 mechanistic role for PTEN in determining the functional outcome of combined pathway blockade.

226 t the level of DNA methylation, modulate the functional outcome of common genetic mutations, such as

227 More generally, we argue that the functional outcome of individual RNA contacts made by an

228 procrustes metric carries information on the functional outcome of injuries in the model.

229 (LAC) reduces the incidence and improves the functional outcome of ischemic stroke.

230 The functional outcome of NMU on NMUR2 was examined using mi

231 However, the functional outcome of PS1 phosphorylation and its signif

232 this work represents the first report of the functional outcome of serine/threonine phosphorylation i

233 trate that Cascade conformation controls the functional outcome of target recognition, enabling tunab

234 the aim of this work was to investigate the functional outcome of the interaction between regDC and

235 c density was negatively correlated with the functional outcome of the paretic limb, as revealed in r

236 n as "readers" that ultimately determine the functional outcome of the post-translational modificatio

237 rom Ub-conjugated substrates to regulate the functional outcome of ubiquitylation.

238 prospective severe sepsis study to elucidate functional outcomes of children suffering septic acute k

239 The result indicates that different functional outcomes of CRISPR-Cas response to two kinds

240 l quality or duration in differentiating the functional outcomes of IL-6 and IL-10 signaling, and ide

241 criptome data valuable for the prediction of functional outcomes of immune responses.

242 pose To report the safety profile and 2-year functional outcomes of in-bore magnetic resonance (MR)-g

243 on to catalytic activity, when assessing the functional outcomes of intellectual disability mutations

244 We investigated the oncological and functional outcomes of neoadjuvant chemoradiotherapy and

245 Here we report functional outcomes of non-nuclear Notch signaling to ac

246 Postdischarge functional outcomes of patients with ischemic stroke wer

247 The primary outcome was change in Functional Outcomes of Sleep Questionnaire (FOSQ) score

248 Sleepiness Scale, Stanford Sleepiness Scale, Functional Outcomes of Sleep Questionnaire, Pittsburgh S

249 Here, we test the functional outcomes of such training.

250 ing genes and generation of RNA chimeras are functional outcomes of transcription read-through.

251 Purpose To determine whether functional outcomes of veterans who sustained combat-rel

252 is predicted following many WGD events, the functional outcomes of WGD need not appear 'explosively'

253 OR's for poor functional outcome on modified Rankin Score (mRS>2) and

254 None of the included studies examined functional outcome or quality of life measures, and card

255 ces among the groups were detected regarding functional outcome or reduction in central foveal thickn

256 no significant between-group differences in functional outcomes or in the rates of death, amputation

257 Addition of laser did not lead to better functional outcomes or lower treatment need.

258 taminophen to naproxen alone did not improve functional outcomes or pain at 1-week follow-up.

259 s superior neurocognitive and neuroendocrine functional outcomes over 5 years without compromising su

260 roke patients are not assessed for long-term functional outcome owing to limited resources and time.

261 year was independently associated with poor functional outcome (P = 0.04), poor cognitive outcome (P

262 seizures were not associated with long-term functional outcome (P = 0.67).

263 this study was to investigate structural and functional outcome parameters and patient satisfaction a

264 Behavioral assays tested for functional outcomes, postmortem analyses assessed neurop

265 as the modified Rankin Scale (mRS) score for functional outcome (range, 0 [no symptoms] to 6 [death])

266 ity rate, decreased infarct volume, improved functional outcome, reduced microglial activation, and r

267 st-ischemic TubA treatment robustly improved functional outcomes, reduced brain infarction, and ameli

268 f spontaneous regeneration resulting in good functional outcome remains uncertain and unnecessary del

269 143 [13%] of 1069 patients in 2013), 3-month functional outcome significantly improved (modified Rank

270 uts, PPI networks drive the cells to diverse functional outcomes such as cell proliferation or cell d

271 ieved to be necessary for arrestin-dependent functional outcomes such as receptor desensitization, en

272 stroke had a higher risk for sICH but better functional outcomes than those who were not receiving an

273 specific activation of Smad3 has contrasting functional outcomes that may involve activation of an in

274 and other clinically relevant parameters on functional outcome to better predict and design future (

275 H) score and to compare its association with functional outcome to that of the original PICH score.

276 with myoclonus after cardiac arrest had good functional outcomes, usually in patients without associa

277 t a model in which EAP deficits lead to poor functional outcome via impaired cognition and increased

278 st-myocardial infarction (MI) structural and functional outcomes via restored S1PR1 signaling, and so

279 adjusted odds ratio for shift toward better functional outcome was 1.0 (95% confidence interval [CI]

280 Good functional outcome was also lower among intubated patien

281 Three-month functional outcome was assessed.

282 Functional outcome was favorable in 19 (50%) patients.

283 ieve one additional patient with independent functional outcome was in the range of 3.2-7.1 and, in m

284 Functional outcome was measured by the Role Functioning

285 Functional outcome was measured using the SF-12 scale.

286 The indirect effect of EAP on functional outcome was significant as well (beta = 0.14,

287 The rate of favorable functional outcome was significantly higher in P2 (127 o

288 cycles per degree, cpd) with structural and functional outcomes was explored with correlation and re

289 Measures of functional outcomes were also administered.

290 Survival and functional outcomes were analyzed.

291 Functional outcomes were assessed by means of Western bl

292 Operative outcomes, long-term survival, and functional outcomes were compared with those of 269 pati

293 Anatomic and functional outcomes were evaluated for patients receivin

294 rd increased mortality (P = 0.079) and worse functional outcomes were seen for the Hp2-2 patients wit

295 revent microvascular obstruction and improve functional outcome when added to the contemporary PCI ma

296 ot cause safety concerns and did not improve functional outcome when given to patients who had ischae

297 with acute ischemic stroke have shown better functional outcomes with endovascular treatment than wit

298 Rankin scale at 2 years; this scale measures functional outcome, with scores ranging from 0 (no sympt

299 at 90 days; this categorical scale measures functional outcome, with scores ranging from 0 (no sympt

300 een early signaling dynamics and later-stage functional outcomes within same cells.